OA11636A - Therapeutic formulation for administering tolterodine with controlled release. - Google Patents

Therapeutic formulation for administering tolterodine with controlled release. Download PDF

Info

Publication number: OA11636A
Authority: OA; OAPI
Prior art keywords: tolterodine; sérum; formulation; métabolite; daims
Prior art date: 1998-08-27

Application number

OA1200000309A

Other languages

English (en)

Inventor

Torkel Gren

Bengt Hallen

Ulla Hoeck

Bo Kreilgard

Helle Kristensen

Lisbeth Nilvebrant

Birgitta Olsson

Lene Orup Jacobsen

Anders Ringberg

Jan Strombom

Martin Wikberg

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-26

Publication date

2004-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11636(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-08-27 Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx

1998-11-11 Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx

1999-08-26 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

2004-09-03 Publication of OA11636A publication Critical patent/OA11636A/en

Links

OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 title claims abstract description 71
229960004045 tolterodine Drugs 0.000 title claims abstract description 71
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 title claims abstract description 71
239000000203 mixture Substances 0.000 title claims abstract description 32
238000013270 controlled release Methods 0.000 title claims abstract description 26
238000009472 formulation Methods 0.000 title claims abstract description 26
230000001225 therapeutic effect Effects 0.000 title claims description 4
239000002775 capsule Substances 0.000 claims description 28
150000001875 compounds Chemical class 0.000 claims description 12
230000002485 urinary effect Effects 0.000 claims description 3
206010046543 Urinary incontinence Diseases 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
230000000694 effects Effects 0.000 description 23
239000003826 tablet Substances 0.000 description 20
206010013781 dry mouth Diseases 0.000 description 16
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 11
239000010410 layer Substances 0.000 description 11
229960005434 oxybutynin Drugs 0.000 description 11
206010039424 Salivary hypersecretion Diseases 0.000 description 10
208000026451 salivation Diseases 0.000 description 10
238000011282 treatment Methods 0.000 description 10
206010020853 Hypertonic bladder Diseases 0.000 description 8
210000003932 urinary bladder Anatomy 0.000 description 8
208000009722 Overactive Urinary Bladder Diseases 0.000 description 7
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 6
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 5
238000000034 method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
208000000921 Urge Urinary Incontinence Diseases 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
206010046494 urge incontinence Diseases 0.000 description 4
-1 2-hydroxy-5-methylphenyl Chemical group 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229960003943 hypromellose Drugs 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000027939 micturition Effects 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000008213 purified water Substances 0.000 description 3
229920001824 Barex® Polymers 0.000 description 2
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
206010036018 Pollakiuria Diseases 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003149 muscarinic antagonist Substances 0.000 description 2
208000020629 overactive bladder Diseases 0.000 description 2
229920006267 polyester film Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000022934 urinary frequency Diseases 0.000 description 2
230000036318 urination frequency Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000003202 urodynamic effect Effects 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
GHXNRYVDXNZXID-UHFFFAOYSA-N 2,2-diethylbutanoic acid Chemical compound CCC(CC)(CC)C(O)=O GHXNRYVDXNZXID-UHFFFAOYSA-N 0.000 description 1
QQFWZTSLZBDZKB-UHFFFAOYSA-N 2-(1-amino-3-phenylpropyl)-4-methylphenol Chemical compound Cc1ccc(O)c(c1)C(N)CCc1ccccc1 QQFWZTSLZBDZKB-UHFFFAOYSA-N 0.000 description 1
WCRNGOULBZMCOR-UHFFFAOYSA-N 2-[2-but-1-ynyl-4-(diethylamino)phenyl]-2-cyclohexyl-2-hydroxyacetic acid Chemical compound CCC#CC1=CC(N(CC)CC)=CC=C1C(O)(C(O)=O)C1CCCCC1 WCRNGOULBZMCOR-UHFFFAOYSA-N 0.000 description 1
LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000035859 Drug effect increased Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
229920003155 Eudragit® RL 100 Polymers 0.000 description 1
229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000012728 immediate-release (IR) tablet Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

OA1200000309A 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release. OA11636A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9802864A SE9802864D0 (sv)	1998-08-27	1998-08-27	Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv)	1998-11-11	1998-11-11	Therapeutic method and formulation

Publications (1)

Publication Number	Publication Date
OA11636A true OA11636A (en)	2004-09-03

Family

ID=26663376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000309A OA11636A (en)	1998-08-27	1999-08-26	Therapeutic formulation for administering tolterodine with controlled release.

Country Status (30)

Country	Link
US (1)	US6770295B1 (is)
EP (2)	EP2153825A1 (is)
CN (1)	CN1239152C (is)
AP (1)	AP1529A (is)
AR (1)	AR029311A1 (is)
AT (1)	ATE487471T1 (is)
AU (1)	AU745190B2 (is)
BG (1)	BG65168B1 (is)
CA (1)	CA2311755C (is)
CY (1)	CY1111088T1 (is)
CZ (1)	CZ302630B6 (is)
DE (1)	DE69942928D1 (is)
DK (1)	DK1039882T3 (is)
EA (1)	EA002720B1 (is)
GE (1)	GEP20043354B (is)
HU (1)	HUP0100437A3 (is)
ID (1)	ID25824A (is)
IL (1)	IL136294A (is)
IS (1)	IS2976B (is)
ME (1)	ME00850B (is)
MY (1)	MY127946A (is)
NO (1)	NO329830B1 (is)
NZ (1)	NZ504618A (is)
OA (1)	OA11636A (is)
PT (1)	PT1039882E (is)
SI (1)	SI1039882T1 (is)
SK (1)	SK287111B6 (is)
TR (1)	TR200001998T1 (is)
UA (1)	UA72882C2 (is)
WO (1)	WO2000012069A1 (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0957073A1 (en) *	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de)	1999-05-18	2000-12-28	Sanol Arznei Schwarz Gmbh	Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) *	1999-07-13	2001-01-18	Hexal Ag	Transdermales therapeutisches System zur Anwendung von Tolterodin
DK1227806T3 (da)	1999-11-11	2005-10-31	Pfizer Health Ab	Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
DE10149674A1 (de)	2001-10-09	2003-04-24	Apogepha Arzneimittel Gmbh	Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US20030185882A1 (en)	2001-11-06	2003-10-02	Vergez Juan A.	Pharmaceutical compositions containing oxybutynin
MXPA04003866A (es) *	2001-11-09	2004-07-08	Pharmacia Ab	Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US6773421B2 (en)	2001-12-14	2004-08-10	Kimberly-Clark Worlwide, Inc.	Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PT1572173E (pt) *	2002-12-13	2010-05-10	Warner Lambert Co	Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
AU2004206110A1 (en) †	2003-01-22	2004-08-05	Pfizer Health Ab	Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) *	2003-04-08	2004-11-18	Schwarz Pharma Ag	Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) *	2003-05-30	2006-03-22	Ranbaxy Laboratories, Ltd.	Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US8709476B2 (en)	2003-11-04	2014-04-29	Supernus Pharmaceuticals, Inc.	Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (is)	2003-11-04	2011-02-17	Supernus Pharmaceuticals Inc
WO2005105036A1 (en) *	2004-04-28	2005-11-10	Natco Pharma Limited	Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) *	2004-08-27	2006-03-01	KRKA, D.D., Novo Mesto	Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en)	2005-04-06	2011-11-15	Adamas Pharmaceuticals, Inc.	Methods and compositions for the treatment of CNS-related conditions
RU2301086C2 (ru) *	2004-12-27	2007-06-20	Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ)	Способ лечения гиперактивного мочевого пузыря
CN1330297C (zh) *	2005-07-04	2007-08-08	宛六一	酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) *	2005-07-22	2007-01-25	주식회사종근당	경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
PT3095447T (pt)	2006-02-03	2022-01-24	Opko Renal Llc	Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
EP2015735A1 (en) *	2006-04-21	2009-01-21	Synthon B.V.	Tolterodine beads
DK2037936T3 (da)	2006-06-21	2014-09-22	Opko Renal Llc	Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
ES3047207T3 (en)	2007-04-25	2025-12-03	Opko Renal Llc	Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko)	2007-04-25	2017-01-02	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en)	2007-04-25	2018-03-06	Cytochroma Inc.	Method of treating vitamin d insufficiency and deficiency
CL2008001970A1 (es) *	2007-07-03	2009-03-27	Synthon Bv	Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) *	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations
US8871275B2 (en)	2007-08-08	2014-10-28	Inventia Healthcare Private Limited	Extended release compositions comprising tolterodine
US20090192228A1 (en) *	2008-01-28	2009-07-30	Actavis Group Ptc Ehf	Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) *	2008-02-26	2009-08-27	Lai Felix S	Controlled Release Muscarinic Receptor Antagonist Formulation
ES2593356T3 (es)	2008-04-02	2016-12-07	Opko Ireland Global Holdings, Ltd.	Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
TWI630208B (zh)	2008-12-08	2018-07-21	歐陸斯迪公司	二氫羥戊甲嗎啡
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
RU2396920C1 (ru) *	2008-12-29	2010-08-20	Николай Владимирович Карюкин	Способ лечения гиперактивного мочевого пузыря
WO2011095388A1 (en)	2010-02-04	2011-08-11	Synthon Bv	Tolterodine bead
KR101746204B1 (ko) *	2010-02-18	2017-06-13	에스케이케미칼주식회사	피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
US11672809B2 (en)	2010-03-29	2023-06-13	Eirgen Pharma Ltd.	Methods and compositions for reducing parathyroid levels
CA2796877A1 (en)	2010-04-30	2011-11-03	Merck Sharp & Dohme Corp.	Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) *	2010-06-17	2011-12-22	Grünenthal GmbH	Transdermale Verabreichung von Memantin
WO2012017892A1 (ja) *	2010-08-03	2012-02-09	久光製薬株式会社	貼付剤及びその粘着力増強方法
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en)	2013-05-30	2013-07-17	Euro Celtique Sa	Method
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko)	2016-03-28	2018-11-14	옵코 아일랜드 글로벌 홀딩스 리미티드	비타민 d 치료 방법
EP3808336A1 (de) *	2019-10-16	2021-04-21	ADD Advanced Drug Delivery Technologies, Ltd.	Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3598123A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US4008719A (en) *	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US5382600A (en) *	1988-01-22	1995-01-17	Pharmacia Aktiebolag	3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv)	1988-01-22	1988-01-22	Kabivitrum Ab	Nya aminer, deras anvendning och framstellning
ES2137261T3 (es) *	1992-05-13	1999-12-16	Alza Corp	Administracion transdermica de oxibutinina.
SE9203318D0 (sv)	1992-11-06	1992-11-06	Kabi Pharmacia Ab	Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) *	1993-11-24	1998-11-11	Lilly Co Eli	Pharmaceutical composition for treatment of incontinence
AU7994694A (en) *	1994-10-21	1996-05-15	Leiras Oy	Controlled release oral delivery system containing oxybutynin
US5677346A (en) *	1995-01-31	1997-10-14	Sepracor, Inc.	Treating urinary incontinence using (S)-desethyloxybutynin
US6310103B1 (en)	1996-07-19	2001-10-30	Bridge Pharma, Inc.	S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0927034A1 (en)	1996-09-19	1999-07-07	American Home Products Corporation	Method of treating urinary incontinence

1999
- 1999-08-26 SK SK749-2000A patent/SK287111B6/sk not_active IP Right Cessation
- 1999-08-26 AT AT99946521T patent/ATE487471T1/de active
- 1999-08-26 US US09/582,498 patent/US6770295B1/en not_active Expired - Lifetime
- 1999-08-26 AR ARP990104280A patent/AR029311A1/es not_active Application Discontinuation
- 1999-08-26 ID IDP20001006A patent/ID25824A/id unknown
- 1999-08-26 NZ NZ504618A patent/NZ504618A/xx not_active IP Right Cessation
- 1999-08-26 EP EP09173927A patent/EP2153825A1/en not_active Withdrawn
- 1999-08-26 HU HU0100437A patent/HUP0100437A3/hu unknown
- 1999-08-26 WO PCT/SE1999/001463 patent/WO2000012069A1/en not_active Ceased
- 1999-08-26 CZ CZ20001924A patent/CZ302630B6/cs not_active IP Right Cessation
- 1999-08-26 IL IL13629499A patent/IL136294A/en unknown
- 1999-08-26 SI SI9931050T patent/SI1039882T1/sl unknown
- 1999-08-26 GE GE3951A patent/GEP20043354B/en unknown
- 1999-08-26 ME MEP-2001-331A patent/ME00850B/me unknown
- 1999-08-26 DK DK99946521.4T patent/DK1039882T3/da active
- 1999-08-26 MY MYPI99003665A patent/MY127946A/en unknown
- 1999-08-26 CN CNB99801916XA patent/CN1239152C/zh not_active Expired - Lifetime
- 1999-08-26 PT PT99946521T patent/PT1039882E/pt unknown
- 1999-08-26 TR TR2000/01998T patent/TR200001998T1/xx unknown
- 1999-08-26 UA UA2000052950A patent/UA72882C2/uk unknown
- 1999-08-26 EA EA200000468A patent/EA002720B1/ru not_active IP Right Cessation
- 1999-08-26 DE DE69942928T patent/DE69942928D1/de not_active Expired - Lifetime
- 1999-08-26 AP APAP/P/2000/001823A patent/AP1529A/en active
- 1999-08-26 OA OA1200000309A patent/OA11636A/en unknown
- 1999-08-26 CA CA2311755A patent/CA2311755C/en not_active Expired - Lifetime
- 1999-08-26 EP EP99946521A patent/EP1039882B1/en not_active Revoked
- 1999-08-26 AU AU58918/99A patent/AU745190B2/en not_active Expired
2000
- 2000-05-26 BG BG104476A patent/BG65168B1/bg unknown
- 2000-06-09 NO NO20002977A patent/NO329830B1/no not_active IP Right Cessation
- 2000-06-15 IS IS5537A patent/IS2976B/is unknown
2010
- 2010-11-17 CY CY20101101027T patent/CY1111088T1/el unknown

Also Published As

Publication number	Publication date
IL136294A (en)	2004-02-08
GEP20043354B (en)	2004-04-13
SI1039882T1 (sl)	2011-01-31
HUP0100437A3 (en)	2002-08-28
AU5891899A (en)	2000-03-21
SK7492000A3 (en)	2001-02-12
DK1039882T3 (da)	2011-01-24
UA72882C2 (uk)	2005-05-16
NO20002977L (no)	2000-06-09
HK1034664A1 (en)	2001-11-02
CN1287484A (zh)	2001-03-14
ID25824A (id)	2000-11-09
TR200001998T1 (tr)	2001-01-22
AP1529A (en)	2006-01-03
IL136294A0 (en)	2001-05-20
AU745190B2 (en)	2002-03-14
NO20002977D0 (no)	2000-06-09
IS5537A (is)	2000-06-15
BG104476A (en)	2000-12-29
CZ302630B6 (cs)	2011-08-10
EA200000468A1 (ru)	2000-12-25
CY1111088T1 (el)	2015-06-11
SK287111B6 (sk)	2009-12-07
AP2000001823A0 (en)	2000-06-30
AR029311A1 (es)	2003-06-25
PT1039882E (pt)	2011-01-03
HUP0100437A2 (hu)	2002-05-29
NO329830B1 (no)	2011-01-03
EP1039882A1 (en)	2000-10-04
BG65168B1 (bg)	2007-05-31
CN1239152C (zh)	2006-02-01
CA2311755C (en)	2010-03-23
US6770295B1 (en)	2004-08-03
WO2000012069A1 (en)	2000-03-09
MY127946A (en)	2007-01-31
CA2311755A1 (en)	2000-03-09
EA002720B1 (ru)	2002-08-29
CZ20001924A3 (cs)	2001-04-11
NZ504618A (en)	2002-09-27
EP1039882B1 (en)	2010-11-10
EP2153825A1 (en)	2010-02-17
ATE487471T1 (de)	2010-11-15
IS2976B (is)	2017-07-15
ME00850B (me)	2008-08-07
DE69942928D1 (de)	2010-12-23

Publication	Publication Date	Title
US6770295B1 (en)	2004-08-03	Therapeutic formulation for administering tolterodine with controlled release
ES2353765T3 (es)	2011-03-04	Formulación terapeútica para administrar tolterodina con liberación controlada.
US6630162B1 (en)	2003-10-07	Pharmaceutical formulation and its use
TWI222879B (en)	2004-11-01	Release-controlled pharmaceutical compositions for treating dysfunction of urinary bladder
US7544372B2 (en)	2009-06-09	Modified release dosage forms of skeletal muscle relaxants
AU2016228002A1 (en)	2017-09-14	Tesofensine, beta blocker combination formulation
MXPA00005215A (en)	2001-12-04	Therapeutic formulation for administering tolterodine with controlled release
HK1034664B (en)	2006-09-08	Therapeutic formulation for administering tolterodine with controlled release